Overall, regardless of which isoform generates Hsp72 protein expression, our data show that suppression of Hsp72 induction enhances bortezomib sensitivity, and support the further development of HSF1 and Hsp72 inhibitors to increase bortezomib sensitivity in bladder cancers. The gene discussed is HSF1; the disease is urinary bladder carcinoma.